FHA
NBIX icon

Flagship Harbor Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Flagship Harbor Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,246
Closed -$119K – 1290
2020
Q3 		$119K Sell
1,246
-598
-32% -$69.2K 0.02% 604
2020
Q2 		$224K Hold
1,844
– – 0.03% 434
2020
Q1 		$160K Buy
1,844
+929
+102% +$90.9K 0.03% 439
2019
Q4 		$98K Buy
915
+165
+22% +$17.3K 0.02% 614
2019
Q3 		$67K Buy
+750
New +$70.1K 0.01% 693
2018
Q4 		– Sell
-76
Closed -$9K – 2010
2018
Q3 		$9K Buy
+76
New +$8.62K ﹤0.01% 1480

Other funds holding NBIX

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Flagship Harbor Advisors's NBIX Position: Q4 2020 in Review

Flagship Harbor Advisors sold out of Neurocrine Biosciences (NBIX) in Q4 2020, closing a stake of 1,246 shares — an estimated $119K sold.

Flagship Harbor Advisors first reported a position in NBIX in Q3 2018 and held it in 6 quarters. The position peaked at $224K in Q2 2020. 406 funds tracked by Wall St. Rank hold NBIX as of Q4 2020.

  • Flagship Harbor Advisors reported no remaining Neurocrine Biosciences position as of Q4 2020 after selling out during the quarter.
  • Flagship Harbor Advisors sold 1,246 Neurocrine Biosciences shares in Q4 2020, an estimated $119K.
  • Flagship Harbor Advisors first reported a position in Neurocrine Biosciences in Q3 2018 and held it in 6 quarters.
  • Flagship Harbor Advisors's Neurocrine Biosciences position peaked at $224K in Q2 2020.
  • 406 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2020.

Based on Flagship Harbor Advisors's 13F filing for Q4 2020, filed 8 Feb 2021.